Valeant To Shell Out $58M To End Solodyn Pay-For-Delay MDL
By Dani Kass ( March 1, 2018, 9:02 PM EST) -- Valeant Pharmaceuticals International Inc. on Wednesday said it will pay more than $58 million to end pay-for-delay litigation in Massachusetts federal court alleging subsidiary Medicis Pharmaceutical Corp. illegally kept a generic for the acne medication Solodyn off the market....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.